A Data Collection Study for Patients With Adenocarcinoma Treated With the MyVaccx Immunotherapy Regimen. (NIRPA)

Gary Onik MD

Status: Completed

Conditions: Adenocarcinoma

Treatments: Drug: Immunotherapeutic Agents; Device: Ablation

Study type: Observational

Identifiers

NCT03695835

NIRPA

Details and patient eligibility

About

A retrospective and prospective data collection study on 27 consecutive subjects with adenocarcinoma who were treated using the MyVaccx system by Dr. Gary Onik. Retrospective data were collected on the treatment with the immunotherapy system and prospective data will be collected as they are prospectively monitored through their normal standard of care for their original cancer.

Enrollment: 27 patients

Sex: All

Ages: 19+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Treatment with the MyVaccx System
• Greater than 18 years of age
• Signature of the informed consent

Exclusion criteria

• 2 subjects treated with the MyVaccx System with known visceral disease

Trial design

27 participants in 1 patient group

Adenocarcinoma treated with MyVaccx

Description:

MyVaccx combines tumor ablation and immunotherapeutic agents for treatment of late stage cancer disease..

Treatment:

Device: Ablation

Drug: Immunotherapeutic Agents